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Pathogenic antibodies targeting the aquaporin-4 water channel on astrocytes are associated with relapsing inflammatory neuro-
myelitis optica spectrum disorders. The clinical phenotype is characterized by recurrent episodes of optic neuritis, longitudinally
extensive transverse myelitis, area postrema attacks and less common brainstem and cerebral events. Patients often develop major
residual disability from these attacks, so early diagnosis and initiation of attackpreventing medications is important. Accurate
prediction of relapse would assist physicians in counselling patients, planning treatment and designing clinical trials. We used a
large multicentre dataset of 441 patients from the UK, USA, Japan and Martinique who collectively experienced 1976 attacks, and
applied sophisticated mathematical modelling to predict likelihood of relapse and disability at different time points. We found that
Japanese patients had a lower risk of subsequent attacks except for brainstem and cerebral events, with an overall relative relapse
risk of 0.681 (P = 0.001) compared to Caucasians and African patients, who had a higher likelihood of cerebral attacks, with a
relative relapse risk of 3.309 (P = 0.009) compared to Caucasians. Female patients had a higher chance of relapse than male
patients (P = 0.009), and patients with younger age of onset were more likely to have optic neuritis relapses (P5 0.001).
Immunosuppressant drugs reduced and multiple sclerosis disease-modifying agents increased the likelihood of relapse
(P50.001). Patients with optic neuritis at onset were more likely to develop blindness (P50.001), and those with older age
of onset were more likely to develop ambulatory disability. Only 25% of long-term disability was related to initial onset attack,
indicating the importance of early attack prevention. With respect to selection of patients for clinical trial design, there would be no
gain in power by selecting recent onset patients and only a small gain by selecting patients with recent high disease activity. We
provide risk estimates of relapse and disability for patients diagnosed and treated with immunosuppressive treatments over the
subsequent 2, 3, 5 and 10 years according to type of attack at onset or the first 2-year course, ethnicity, sex and onset age. This
study supports significant effects of onset age, onset phenotype and ethnicity on neuromyelitis optica spectrum disorders outcomes.
Our results suggest that powering clinical treatment trials based upon relapse activity in the preceding 2 years may offer little
benefit in the way of attack risk yet severely hamper clinical trial success.
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Introduction
The neuromyelitis optica spectrum disorders (NMOSD) are
autoimmune, inflammatory disorders of the CNS with a
predilection for the optic nerves and spinal cord and are
distinct from multiple sclerosis (Wingerchuk et al., 2007).
The majority of patients have antibodies to aquaporin-4
(AQP4) water channels, which are situated predominantly
on astrocyte foot processes; hence AQP4-IgG-positive
NMOSD is now recognized as an autoimmune astrocyto-
pathy with secondary demyelination (Lennon et al., 2004,
2005). The AQP4-IgG seronegative group (considered sero-
negative NMOSD) likely represents a heterogeneous group
of both monophasic and relapsing inflammatory CNS dis-
orders that include post-infectious inflammation and condi-
tions caused by unidentified antibodies (Wingerchuk et al.,
2015). Recently some patients in this group have been re-
ported to be positive for antibodies targeting myelin oligo-
dendrocyte glycoprotein (MOG) and these patients have a
primary demyelinating disorder (Waters et al., 2015; Jarius
et al., 2016; Peschl et al., 2017).
There are important differences between those who are
seropositive for AQP4-IgG and MOG-IgG. AQP4-IgG-posi-
tive NMOSD in contrast to MOG-antibody-associated disor-
ders (MOGAD) is far more common in females (Quek et al.,
2012), has a non-Caucasian ethnic bias, commonly co-asso-
ciates with other autoantibodies and diseases, is relapsing if
untreated and is associated with significant morbidity and
mortality from relapse-related disability (Kitley et al., 2014b;
Flanagan et al., 2016; Jurynczyk et al., 2017; Cobo-Calvo
et al., 2018; Jitprapaikulsan et al., 2018a, b). Additionally,
current immunosuppressive treatments (ISTs), such as pred-
nisolone, azathioprine, mycophenolate mofetil and rituximab,
may not suppress the disease adequately. Thus there is a
growing interest in developing new treatments and currently
there are three immune-modulatory drugs being tested in
international multicentre phase 4 randomized controlled
trials: inebilizumab (anti-CD19 monoclonal antibody target-
ing B cells), eculizumab (anti-C5 monoclonal antibody
targeting complement) and two utilizing satralizumab
(anti-IL-6R monoclonal antibody targeting T and B cell acti-
vation, Th17 differentiation, and plasmablast survival). These
studies enrol exclusively or primarily patients with AQP4
antibodies.
Because the outcomes across patients with AQP4-IgG-posi-
tive NMOSD are heterogeneous and because data that permit
power calculations for clinical trials are sparse (Weinshenker
et al., 2015), we combined datasets from five centres with
detailed prospective data collection systems, across four coun-
tries with varied ethnicities. We developed a joint modelling
framework to understand the factors that influence relapses
and disability and predict future attacks and disability events.
Materials and methods
Patient cohort
An international database was created by merging prospectively
collected datasets from five neuromyelitis optica (NMO) specia-
lized centres: Oxford and Liverpool (UK), Mayo Clinic (USA),
Sendai (Japan) and Martinique. Information collected included
sex, ethnicity, onset attack type (optic neuritis, transverse myelitis,
brainstem attack, cerebral, and mixed), age at onset, Expanded
Disability Status Scale (EDSS) scores and visual acuity and
chronic immunomodulatory treatment. All data were anon-
ymized and satisfied the local ethics requirements.
Analysis
We represented each type of recurrent NMO attacks as a
counting process with an intensity (rate) function dependent
on baseline covariates and treatment histories, as well as un-
observed random effects. The model is an extension of the well
known multiplicative intensity model of Andersen and Gill
(1982) to accommodate multiple types of recurrent events
and to account for patient heterogeneity or clustering of recur-
rent attacks. There is a shared random effect that characterizes
the patient’s overall propensity for recurrent attacks, as well as
a type-specific random effect that characterizes the patient’s
propensity for each type of recurrent attacks. The values of
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the random effects vary among patients, representing the pa-
tient characteristics that are not captured by the measured
covariates. The mean of the random effect in the population
is set to zero. A patient with a positive value of the random
effect tends to have more attacks than an average patient,
whereas a patient with a negative value of the random effect
tends to have fewer attacks than an average patient. The vari-
ance of the random effect reflects the degree of heterogeneity,
with a larger value indicating greater heterogeneity.
We formulated the effects of baseline covariates and treat-
ment histories on the hazard function of a disability event
through a proportional hazards model (Cox, 1972) in which
the shared random effect from the model for recurrent attacks
enters as an additional covariate. The regression coefficient for
the shared random effect captures the dependence of disability
on recurrent attacks. This joint modelling approach allows us
to assess the effects of baseline covariates and time-dependent
covariates (e.g. treatments) on the rate of recurrence for each
type of NMO attack and on the risk of occurrence for each
type of disability while accounting for the patient heterogeneity
that is not accounted for by the measured covariates. It also
allows us to predict future attacks and disability events using
not only the baseline characteristics and treatment histories but
also the event histories. This model uses a time-dependent ana-
lysis which allows for any variation in follow-up times across
the different covariate subgroups. The mathematical formula-
tion, estimation procedure, and prediction algorithm are de-
tailed in the Supplementary material.
For the baseline covariates we included ethnicity, sex, age at
disease onset, and baseline attack type. We classified patients
according to five major ethnicity groups: Caucasian, African
(includes all those of African descent), Hispanic, Japanese, and
non-Japanese Asian. We combined Hispanic and unknown
ethnicity with Caucasian, which serves as the reference. We
divided patients into three age groups according to the tertiles:
435 years, 35–48 years, and 448 years, with the last tertile
as the reference. Such tertiles were used as a balanced distri-
bution yields more stable estimates. The clinical and demo-
graphic characteristics of each tertile are shown in
Supplementary Table 1. For the baseline attack, we combined
brainstem and cerebral and set transverse myelitis as the
reference.
There were two time-dependent covariates: ISTs were com-
bined into one group (chronic prednisolone/prednisone,
azathioprine, mycophenolate, rituximab, methotrexate or any
combination) and were allocated the value of 0 before initi-
ation of the IST treatment and the value of 1 afterwards;
licensed multiple sclerosis disease-modifying treatments were
combined as one group (multiple sclerosis disease-modifying
treatment: mainly interferon beta and glatiramer acetate;
anti-CD20 monoclonals were not included in this group) and
were allocated the value of 1 between the starting and stop-
ping dates and the value of 0 otherwise. No patients were
treated with natalizumab or ocrelizumab. The treatment com-
parisons pertain to IST versus no treatment and multiple scler-
osis disease-modifying treatments versus no treatment.
We combined some types of events in order to increase
power and stability. Specifically, we combined unilateral and
bilateral optic neuritis, classified unknown attack types (13 of
1976 events, 0.7%) as transverse myelitis attacks, which were
the most common type, used the composite endpoint of one-
eye blindness and two-eye blindness and the composite end-
point of EDSS 8.0 and death.
The results are based on the joint model with four types of
NMO attacks (i.e. optic neuritis, transverse myelitis, brain-
stem, and cerebral) and the disability events of blindness and
EDSS 6.0, except for the results on EDSS 8.0/death, which are
based on a second joint model with EDSS 6.0 replaced by
EDSS 8.0/death, and for the results on all relapses, which com-
bine the four types of NMO attacks into a single sequence of
recurrent events. If a patient had a mix of optic neuritis and
transverse myelitis, then he/she would contribute to both types
of events in the analysis.
Data availability
The data that support the findings of this study are available
from the corresponding authors, upon request.
Results
Clinical and demographic
characteristics of the international
NMOSD attack database
A total of 441 AQP4-IgG-positive NMOSD patients from
the five sites were included (Table 1). There were 396 fe-
males and 45 males. The age of onset ranged from 2.7 to
82.7 years, with a median of 40.8 years. Over a median
disease duration of 7.1 years (range: 0.3–46.6), 1976 at-
tacks were documented. Supplementary Table 2 shows the
frequencies and types of attacks and disability outcomes
during the disease course according to baseline characteris-
tics, such as attack type, site and ethnicity.
Effects of age, sex, ethnicity and
treatment on likelihood of relapse
The estimation results for the effects of covariates on re-
current NMO attacks after disease onset (in terms of rate
ratio) are summarized in Table 2. Japanese patients had the
lowest risk of relapses overall but the highest brainstem
attack risk, and African patients had the highest cerebral
attack risk. Compared to Caucasian patients (the reference
group in the analysis), Japanese patients had lower risk of
recurrent attacks (P = 0.001), particularly transverse myeli-
tis attacks (P = 0.001) and optic neuritis attacks
(P = 0.026), and African patients had much higher risk
for cerebral attacks (P = 0.009). Female patients had
higher recurrence rates for transverse myelitis attacks
(P5 0.001) and overall relapses (P = 0.009) than male pa-
tients. Patients with younger age of onset were more likely
to have optic neuritis relapses (P5 0.001) than older pa-
tients. In general, the onset attack type was positively asso-
ciated with relapse of the same attack phenotype. ISTs
reduced the likelihood of all relapses by 33%
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(P50.001), with greater effects on optic neuritis, trans-
verse myelitis and cerebral attacks (Fig. 1), whereas mul-
tiple sclerosis disease-modifying treatments increased the
risk of relapse. Supplementary Fig. 1 shows that the risk
of relapse decreases over time, most dramatically after 10
years.
Effects of age, sex and ethnicity on
likelihood of developing disability or
blindness
The estimation results for the effects of covariates on the
likelihood of developing disability (EDSS5 6) or blindness
Table 1 Demographics of AQP4-IgG-positive NMOSD patients
Total Japan Oxford Liverpool Martinique Mayo
Total patients 441 63 77 74 56 171
Ethnicity
Caucasian 210 0 50 54 1 105
African 115 0 17 11 54 33
Asian 100 63 10 7 1 19
Hispanic 11 0 0 0 0 11
Mixed/unknown 5 0 0 2 0 3
Sex
Male 45 3 9 12 3 18
Female 396 60 68 62 53 153
Age at onset
Mean (standard deviation, SD) 41.2 (15.4) 43.1 (14) 39.3 (18.3) 41.5 (15.6) 38.1 (15.8) 42.3 (14.1)
Duration of follow-up from onset
Median, years 7.1 7.2 6.3 6.8 7.0 8.2
(range) (0.3–46.6) (0.3–44.2) (0.4–34.4) (0.5–38.4) (0.5–37.1) (0.3–46.6)
Table 2 Estimation of the effects of covariates on the rates of recurrence for attacks
Optic neuritis Transverse myelitis Brainstem Cerebral All
Covariate Rate ratio P-value Rate ratio P-value Rate ratio P-value Rate ratio P-value Rate ratio P-value
Site ethnicity
African 0.968 (0.188) 0.865 0.963 (0.120) 0.761 0.813 (0.310) 0.588 3.309 (1.517) 0.009 1.003 (0.099) 0.974
Japanese 0.587 (0.141) 0.026 0.588 (0.092) 0.001 1.651 (0.575) 0.150 1.719 (0.921) 0.312 0.681 (0.076) 0.001
Non-Japanese Asian 1.124 (0.292) 0.653 0.921 (0.178) 0.669 0.617 (0.402) 0.458 0.717 (0.631) 0.706 1.010 (0.138) 0.940
USA Caucasian
and others
1 – 1 – 1 – 1 – 1 –
Sex
Female 0.903 (0.145) 0.524 1.501 (0.167) 50.001 0.860 (0.316) 0.681 1.596 (0.711) 0.294 1.209 (0.087) 0.009
Male 1 – 1 – 1 – 1 – 1 –
Age, years
435 2.078 (0.393) 50.001 0.872 (0.114) 0.295 1.767 (0.643) 0.118 0.823 (0.414) 0.698 1.090 (0.104) 0.365
35–48 1.468 (0.296) 0.057 0.790 (0.105) 0.075 1.942 (0.762) 0.091 1.507 (0.765) 0.419 0.930 (0.090) 0.456
448 1 – 1 – 1 – 1 – 1 –
Baseline attack
Optic neuritis 1.608 (0.270) 0.005 0.836 (0.103) 0.146 0.838 (0.306) 0.627 1.145 (0.509) 0.761 1.026 (0.096) 0.783
Brainstem/cerebral 1.686 (0.498) 0.077 1.084 (0.216) 0.685 3.903 (1.636) 0.001 2.929 (1.518) 0.038 1.287 (0.197) 0.098
Mixed 0.992 (0.293) 0.978 0.893 (0.139) 0.470 1.719 (0.750) 0.215 2.284 (1.180) 0.110 0.936 (0.114) 0.584
Transverse myelitis 1 – 1 – 1 – 1 – 1 –
Treatment
IST 0.662 (0.064) 50.001 0.611 (0.042) 50.001 0.900 (0.220) 0.665 0.486 (0.172) 0.042 0.668 (0.028) 50.001
MS-DMT 1.325 (0.242) 0.124 1.382 (0.142) 0.002 0.672 (0.377) 0.479 1.941 (0.852) 0.131 1.383 (0.107) 50.001
No treatment 1 – 1 – 1 – 1 – 1 –
Standard errors are shown in parentheses.
MS-DMT = multiple sclerosis disease-modifying treatment.
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(in terms of hazard ratio) are summarized in Table 3.
African patients were more likely to develop blindness
and Japanese patients least likely to reach EDSS 8.0/
death; both differences were significant compared to the
reference Caucasian group. Females had higher risk for
all types of disability events. Patients with a younger age
of onset were not only more likely to develop recurrent
optic neuritis but also had a higher likelihood of developing
blindness. They had a lower risk of developing EDSS 6.0
and EDSS 8.0 or death. In contrast, patients in the oldest
age of onset group had a significantly higher likelihood of
having ambulatory disability (need for cane or wheelchair)
compared with those in the two younger age groups.
Patients with optic neuritis or mixed onset attacks were
more likely to develop blindness (P50.001). Although
ISTs were associated with a lower likelihood and multiple
sclerosis disease-modifying agents were associated with a
higher likelihood of blindness and EDSS 6.0, neither
reached statistical significance. In contrast, both ISTs and
multiple sclerosis disease-modifying agents were associated
with a higher likelihood of reaching EDSS58 although
there were fewer events.
The estimation results for the random effects are pre-
sented in Supplementary Table 3. The variances of the
shared and type-specific random effects are all quite large,
indicating strong patient heterogeneity (due to unobserved
Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis;
TM = transverse myelitis.
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confounders) in recurrent NMO attacks, especially for
optic neuritis and transverse myelitis attacks. In addition,
recurrent NMO attacks substantially increase the risks for
all types of disability. Specifically, the coefficients of the
shared random effect for blindness, EDSS 6.0, and EDSS
8.0/death are all estimated at 1.5, indicating that a half
unit change in the shared random effect for recurrent at-
tacks would double the risk of each type of disability event.
Relationship between onset attack
and significant long-term disability
Only 25% of patients who experienced EDSS56 reached
that disability milestone due to the onset attack. Only 17%
of patients experiencing EDSS 8.0 reached that disability
milestone due to the onset attack. For patients developing
blindness in one or both eyes, 41% and 21%, respectively,
reached that level of disability due to the onset attack.
Thus, most patients require multiple attacks in order to
acquire significant disability.
Predicting risk of relapse and disability
based on age, sex and historical attack
frequency and phenotype
Our model can be used to predict the outcomes of individual
patients according to their characteristics. For example,
Supplementary Fig. 2 displays the estimated cumulative inci-
dence functions of any relapse and an optic neuritis attack after
Year 2 for a Japanese female patient who was diagnosed with
a transverse myelitis attack at age 40 and did not receive mul-
tiple sclerosis disease-modifying treatment. The IST treatment
reduces the incidence of any relapse and optic neuritis attack,
while having two optic neuritis attacks in the first 2 years
substantially increases the incidence of future NMO attacks,
especially optic neuritis attacks. As a second example,
Supplementary Fig. 3 displays the estimated cumulative inci-
dence functions of blindness and EDSS 6.0 after Year 2 for a
Caucasian male patient who was diagnosed at age 30, started
IST at disease onset, and did not receive multiple sclerosis dis-
ease-modifying agents. If such a patient was diagnosed with an
optic neuritis attack as opposed to a transverse myelitis attack
at disease onset, then his risk of blindness is increased by
nearly 3-fold and his risk of EDSS 6.0 is reduced by nearly
40%. Having two new optic neuritis attacks in the first 2 years
increases both the risks of blindness and EDSS 6.0
considerably.
Outcome prediction tables: a helpful
tool for clinicians and patients.
Tables 4–6 provide estimates for the risks of recurrent at-
tacks and disability events over time for patients who were
treated (i.e. with immunosuppressants from onset and
Table 3 Estimation of the effects of covariates on the occurrence of disability events
Blindness EDSS 6.0 EDSS 8.0/death
Covariate Hazard ratio P-value Hazard ratio P-value Hazard ratio P-value
Site ethnicity
African 1.724 (0.248) 50.001 1.059 (0.280) 0.828 0.876 (0.306) 0.704
Japanese 0.853 (0.160) 0.395 0.799 (0.274) 0.514 0.297 (0.154) 0.020
Non-Japanese Asian 1.375 (0.270) 0.105 0.829 (0.316) 0.622 0.628 (0.347) 0.400
USA Caucasian and others 1 – 1 – 1 –
Sex
Female 1.633 (0.258) 0.002 1.522 (0.290) 0.027 1.508 (0.349) 0.076
Male 1 – 1 – 1 –
Age, years
435 1.490 (0.229) 0.009 0.332 (0.090) 50.001 0.339 (0.119) 0.002
35–48 1.284 (0.211) 0.128 0.522 (0.135) 0.012 0.270 (0.109) 0.001
448 1 – 1 – 1 –
Baseline attack
Optic neuritis 3.810 (0.561) 50.001 0.622 (0.162) 0.068 0.832 (0.275) 0.578
Brainstem/cerebral 1.253 (0.446) 0.527 0.726 (0.270) 0.389 0.663 (0.359) 0.448
Mixed 2.153 (0.420) 50.001 0.829 (0.246) 0.526 0.801 (0.321) 0.580
Transverse myelitis 1 – 1 – 1 –
Treatment
IST 0.735 (0.126) 0.072 0.708 (0.141) 0.082 1.647 (0.409) 0.045
MS-DMT 1.498 (0.399) 0.129 1.511 (0.502) 0.214 1.865 (0.862) 0.177
No treatment 1 – 1 – 1 –
Standard errors are shown in parentheses.
MS-DMT = multiple sclerosis disease-modifying treatment.
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not multiple sclerosis disease-modifying treatments).
We considered 54 combinations of baseline characteristics:
ethnicity (Japanese, Caucasian, African), sex, age group
(535, 35–48, 448), and onset attack type (optic neuritis,
transverse myelitis, brainstem). Table 4 provides risk esti-
mates over the first 2 years. Table 5 and Supplementary
Table 4 provide risk estimates at Year 2 and over the sub-
sequent 2, 3, 5 and 10 years for the patients who have not
reached the disability endpoints at Year 2. Table 5 and
Supplementary Table 4 pertain to patients without any re-
lapse within 2 years after the onset attack. Table 6 and
Supplementary Table 5 provide risk estimates at Year 2
over the subsequent 2, 3, 5 and 10 years for the patients
who have not reached the disability endpoints at Year 2.
Table 6 and Supplementary Table 5 pertain to patients who
had one relapse in the first 2 years after the onset attack.
These prediction tables can be used in the clinic setting to
inform physicians and patients on the choice of initial
treatment.
Optimization of patient recruitment
for clinical trials
Our data can be used to more accurately power future
clinical trials. It is noteworthy that because disability is
solely relapse-related in NMO and because such disability
may be severe (and in contrast to multiple sclerosis), pri-
mary outcome measures in phase 3 NMO clinical trials to
date, have been time to first relapse only (for ethical rea-
sons) as a surrogate for disability. Thus we estimated the
risk of relapsing over a 1- and 2-year period to aid trial
design. Because there are limited restrictions that can eth-
ically be applied to clinical trial eligibility (e.g. sex and
ethnicity criteria would not be acceptable inclusion cri-
teria), we selected baseline characteristics such as prior re-
lapse activity and disease duration to calculate risk of
relapse over the subsequent 1 and 2 years. Table 7 shows
the estimated proportion of patients who relapse over a 1-
year and 2-year period, dependent on the disease duration
category and the number of NMO attacks in the preceding
2 years for those on IST because we assumed all diagnosed
AQP4-IgG-positive patients will be on IST. A patient with
disease duration of 55 years and with at least three attacks
in the past 2 years has 73% chance of relapse within the
next 2 years (representing 2.7% of the NMO population),
whereas any patient (no restriction) has a 54% chance of
relapse in 2 years (representing 100% of the population).
Such information is useful for powering future clinical
trials. The percentage of total AQP4-IgG-positive
NMOSD patients who would satisfy these criteria is also
included in the table because there will be a trade-off be-
tween selecting a rare group of highly active patients versus
a broader range of less active patients; the former is favour-
able for statistical powering purposes whereas the latter
favours ease of recruitment and a broader licensing indica-
tion. The loss of study eligible patients would be more
deleterious to an effective study design than loading the
study with highly active patients. For example, there ap-
pears no overall advantage in selecting recent onset patients
or patients with higher disease activity in the preceding 2
years (used as a criteria for the currently ongoing three
randomized control trials) because the increase in disease
activity is modest and the loss of eligible patients large so
that the entry criteria could be broadened.
Discussion
This study has highlighted several important issues, includ-
ing the effects of ethnicity, sex, onset age, treatment and
onset attack phenotype on relapse and disability risks.
Using these risk factors we have been able to produce a
new useful prognostic tool allowing prediction of the likely
outcome in individual patients according to their baseline
features and at 2 years depending on their early disease
course. Second, we have produced data on the relapse
risk over 1 and 2 years based upon disease activity in the
prior 2 years as a tool to power future clinical treatment
trials, and we have shown that the activity in the prior 2
years has only a modest effect on the subsequent 2 year
activity. Third, we have used a model that removes the
usual before and after treatment biases, and our results
still support the effectiveness of IST and negative effect of
multiple sclerosis drugs in AQP4-IgG-positive NMOSD
patients. Finally, we have shown that the disability is
often due to relapses and not the onset attack, highlighting
the importance of starting treatment soon after the index
clinical event.
Several previous studies have reported risk factors for
relapse and disability using univariate and multivariate re-
gression analysis (Weinshenker et al., 2006; Collongues
et al., 2010a, b, 2014; Jiao et al., 2013; Kim et al.,
2013). The strength of the analysis model in this study is
that it takes into account the timing of the event and allows
time-dependent treatment effects to be used. This will for
example remove the positive bias due to onset attacks
(which occur off treatment) being more severe, independent
of treatment. Additionally we can combine the different
factors in individual patients to produce individual patient
predictions of risk. Importantly in contrast to other models,
we can account for the correlation of recurrent attacks and
disability events accounting for their dependence explicitly
and use the histories of certain events to predict the devel-
opments of other events.
Acknowledging the difference in analysis methods our
findings are generally in line with other studies of AQP4-
IgG-positive NMOSD patients. Kitley et al. (2012), in a
smaller population of AQP4-IgG seropositive patients,
noted better outcomes in Japanese patients than
Caucasians, and although there was no difference in time
to first relapse amongst different ethnic groups, there was a
lower relapse rate in Japanese than in Caucasians and Afro-
Caribbeans. Afro-Caribbeans had the greatest risk of visual
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Table 4 Likelihood (%) of developing attacks and disability by Year 2 for patients on IST from onset
Attack onset Risk within first 2 years after onset
Age, years Type All attacks ON TM BS EDSS Blindness
6.0 58.0
Japanese female
435 ON 51.6 26.5 26.2 11.4 5.7 1.9 25.8
TM 50.1 18.4 30.1 13.3 8.9 2.3 7.9
BS 68.7 27.5 31.9 38.0 6.6 1.5 9.8
36–48 ON 48.0 20.4 24.2 12.4 8.8 1.5 22.8
TM 47.4 13.8 27.9 14.4 13.5 1.8 6.9
BS 67.8 21.1 29.7 40.3 10.1 1.2 8.5
448 ON 44.3 14.9 29.1 6.8 15.7 5.5 18.5
TM 45.1 9.8 33.3 8.0 23.3 6.6 5.4
BS 60.0 15.5 35.3 25.4 17.9 4.4 6.7
Japanese male
435 ON 48.9 28.6 18.7 13.0 3.8 1.3 17.1
TM 46.2 19.9 21.8 15.2 6.0 1.5 5.0
BS 67.4 29.6 23.2 41.8 4.5 1.0 6.2
36–48 ON 44.8 22.1 17.2 14.1 5.9 1.0 15.0
TM 43.3 15.0 20.0 16.4 9.2 1.2 4.3
BS 66.3 22.9 21.4 44.3 6.9 0.8 5.4
448 ON 39.2 16.2 21.0 7.8 10.8 3.7 12.0
TM 38.8 10.8 24.3 9.2 16.5 4.4 3.4
BS 56.1 16.8 26.0 28.4 12.4 3.0 4.2
Caucasian female
435 ON 63.6 38.3 38.8 7.2 7.1 6.2 29.2
TM 61.5 27.7 43.7 8.5 11.0 7.4 9.2
BS 74.3 39.4 46.1 26.7 8.2 5.0 11.3
36–48 ON 58.4 30.3 36.2 7.9 10.8 5.0 26.0
TM 57.2 21.3 41.0 9.3 16.4 6.0 8.0
BS 71.4 31.4 43.2 28.7 12.4 4.0 9.9
448 ON 56.9 22.9 42.6 4.2 19.0 16.8 21.2
TM 57.5 15.6 47.7 5.0 27.8 19.7 6.3
BS 67.7 23.7 50.1 17.0 21.6 13.8 7.8
Caucasian male
435 ON 60.0 40.8 28.8 8.3 4.8 4.2 19.6
TM 56.2 29.8 33.0 9.8 7.5 5.0 5.8
BS 71.6 42.0 35.0 29.9 5.5 3.4 7.2
36–48 ON 54.2 32.6 26.7 9.1 7.3 3.4 17.3
TM 51.5 23.1 30.7 10.6 11.3 4.0 5.0
BS 68.3 33.6 32.6 32.0 8.4 2.7 6.2
448 ON 50.5 24.7 32.0 4.9 13.2 11.7 13.8
TM 49.6 17.0 36.4 5.8 19.9 13.8 3.9
BS 62.0 25.6 38.6 19.3 15.2 9.5 4.9
African female
435 ON 63.2 37.5 37.8 6.0 7.5 5.5 43.2
TM 60.9 27.0 42.7 7.0 11.6 6.6 15.1
BS 74.0 38.6 45.0 22.8 8.6 4.4 18.4
36–48 ON 59.0 29.7 35.3 6.5 11.3 4.4 39.0
TM 57.5 20.8 40.0 7.7 17.2 5.3 13.2
BS 72.3 30.7 42.2 24.6 13.0 3.6 16.1
448 ON 57.1 22.3 41.5 3.5 19.9 15.0 32.6
TM 57.4 15.2 46.6 4.1 29.0 17.6 10.5
BS 68.3 23.1 49.0 14.3 22.6 12.2 12.9
African male
435 ON 59.3 40.0 28.0 6.9 5.0 3.7 30.4
TM 55.3 29.1 32.1 8.1 7.9 4.4 9.7
BS 70.6 41.2 34.0 25.6 5.8 3.0 11.9
36–48 ON 54.1 31.8 25.9 7.5 7.7 3.0 27.1
TM 51.1 22.5 29.8 8.8 11.9 3.6 8.4
BS 68.1 32.9 31.7 27.5 8.9 2.4 10.4
448 ON 50.3 24.1 31.1 4.0 13.9 10.3 22.2
TM 49.1 16.5 35.5 4.8 20.9 12.2 6.7
BS 61.9 25.0 37.6 16.3 15.9 8.4 8.2
BS = brainstem; ON = optic neuritis; TM = transverse myelitis.
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disability than the other groups. There were fewer brain
attacks in Caucasians than other groups. Additionally,
young onset patients were more likely to develop visual
disability and older onset patients to develop motor disabil-
ity and those with optic neuritis onset attacks were more
likely to develop visual disability. Initiating IST before the
first relapse was associated with longer time to relapse.
However, the study had less power and did not adjust
for interactions between race, age and onset phenotype,
did not factor in time-dependent treatment effects nor in-
corporate the effects of relapses and disability over time.
Long et al. (2017) reported in a cohort of 292 Chinese
AQP4-IgG-positive patients an earlier time to relapse in
those presenting with non-optic neuritis non-transverse
myelitis attacks although the relapse rates were eventually
similar to those presenting with optic neuritis or transverse
myelitis (Long et al., 2017). This non-optic neuritis non-
transverse myelitis onset group had lower EDSS scores at
follow-up. However, these outcomes were not adjusted for
other baseline differences such as the younger age of onset
and varied follow-up times. Table 2 from our study shows
that patients with cerebral or brainstem onset attacks had
the highest relapse risk, and Table 3 shows that this group
had non-significant lower risks of visual disability, a similar
risk to optic neuritis but lower risk than transverse myelitis
to reaching EDSS 6.0, and lower risk of EDSS5 8.0.
Seok et al. (2017) noted in Korean AQP4-IgG-positive
patients that those with late onset compared to those
with early onset disease had a lower risk of relapse (al-
though not time to relapse) and subsequent risk of non-
transverse myelitis attacks, a lower risk of visual disability
and a trend to a higher risk of EDSS 6.0; however, differ-
ences between the onset phenotypes, follow-up times, and
use of multiple sclerosis drugs were not adjusted for (Seok
et al., 2017). The authors noted their older onset patients
appeared to have lower EDSS scores than the Caucasian
patients from Kitley et al. (2012).
One important advantage of our analysis model is its
ability to predict the risk of future outcomes in individual
patients at any time point and account for the number of
events (relapses and disability events) already experienced.
This model requires a large dataset and the confidence of
the prediction will depend not only on the size of the data-
set but also on the diversity of the population (age, sex,
ethnicity etc.). We have included two illustrative scenarios:
one from disease onset, which requires the diagnosis of
AQP4-IgG-positive NMOSD to have been made and as-
sumes long-term IST since disease onset, and one at 2
years depending on whether the patients have had no re-
lapse or one relapse over this period and have not reached
the disability endpoint of interest (because 0–1 relapse is
the most common relapse frequency over the first 2 years).
Ideally this model should be set up as an online tool and
continuously updated with more patient data, and individ-
ual risks for all clinical scenarios could be estimated. A
similar tool for multiple sclerosis was developed but not
established because of lack of long-term resources
(Daumer et al., 2007).
We also provided useful information to power future
clinical trials. In contrast to multiple sclerosis, NMO dis-
ability is primarily relapse acquired and because the re-
lapses can be severely disabling, the primary outcome in
NMO trials has been time to relapse. The current phase
3 clinical trials have focused on recruiting active patients
with recent and often multiple relapses. There have been
challenges in recruiting partly due to the rarity of the con-
dition and the smaller subpopulation that meet these cri-
teria. However, it has been assumed that activity in the last
2 years has a large effect on the relapse risk going forward.
Our data suggest that randomizing all patients (assuming
on IST) would produce a reasonable number of relapses
within 1 and 2 years and allow a much greater pool of
patients to recruit from. Restricting recruitment to very
active disease in order to optimize the likelihood of
Table 7 Identification of NMOSD patients for drug trials: risk of relapse at 1 and 2 years based on numbers of attacks
in preceding 2 years
No. of attacks in
the past 2 years
Disease
duration
% of patients that
relapse in 1 year
% of patients that
relapse in 2 years
Average % patients fulfilling
criteria over timea
At least 3 Any 46.60% 67.90% 6.6%
55 years 52.00% 73.30% 2.7%
55 years 44.90% 66.30% 3.9%
At least 2 Any 42.60% 63.70% 17.6%
55 years 46.90% 68.00% 5.0%
55 years 40.20% 62.30% 12.6%
At least 1 Any 38.70% 59.20% 40.7%
55 years 41.10% 62.50% 7.7%
55 years 36.6% 58.20% 33.0%
Any Any 34.50% 54.20% 100%
55 years 37.90% 57.50% 14.8%
55 years 33.40% 53.10% 85.2%
aOn 1 January 2013.
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on-study attacks significantly reduces the pool of eligible
patients prolonging the recruitment period or increasing
the number of centres or both. Our data indicate that
such patient selection criteria only moderately increase re-
lapse risk. Additionally, the drug license may be limited to
patients who meet the study entry criteria and thus expand-
ing the eligibility could broaden access to treatment. Thirty-
four per cent of the total cohort of IST-treated patients
relapsed within 1 year from a single time point and this
appears surprisingly high. A previous letter (Kitley et al.,
2014a, b) noted 25% of all patients from a single time
point (on and off IST) relapsed within 7 months and
50% within 19 months (Kitley et al., 2014a). From onset
of IST, 50% relapsed within 23 months when early relapses
from initiation were included. Neither of these outcomes is
directly comparable to our category of patients but these
data support our figures although we have used a more
practically relevant outcome for clinical trial recruitment
i.e. taking all already on IST.
The lack of randomized controlled trials to support
the use of IST has been used to advocate the use of pla-
cebo-controlled trials in neuromyelitis optica. Cree (2015)
noted the biases of using before (historical) and after (post-
initiation of IST) comparisons of relapse rates, such as re-
gression towards the mean (Cree, 2015). Additionally the
natural history of reduction of relapses over time we have
demonstrated would add to this bias. Although not rando-
mized controlled data, our analysis removes these biases
and shows a positive effect of IST in all relapse and dis-
ability outcomes except for EDSS 8.0/death. There ap-
peared a negative effect of IST on this latter outcome and
this is out of keeping with the other IST effects in our
cohort and would be at odds with the literature, thus we
think this is likely to be a random effect due to the smaller
numbers for this outcome.
The purpose of this study was not to compare efficacy of
different immunosuppressive medications as attack prevent-
ive therapies in NMOSD. Most but not all previous obser-
vational studies suggest that rituximab is more effective than
azathioprine (Mealy et al., 2014; Jeong et al., 2016;
Stellmann et al., 2017). Furthermore, a recent randomized
controlled trial also showed superiority of rituximab over
azathioprine at relapse prevention (Nikoo et al., 2017).
Our non-randomized allocation of treatments would not
have added better evidence to the literature and would
have reduced our ability to see the influences of other factors
on outcome. Lumping all ISTs together does not include a
bias because it is standard practice in all centres to advise all
AQP4-IgG-positive patients to take ISTs. Additionally if we
split the groups into more subgroups it reduces the power to
see the effects of relevant and unbiased covariates. For ex-
ample, there were only 20 patients who started with ritux-
imab as the first line treatment, and among them, only six
experienced disability events. We, therefore, did not analyse
separately all the different IST or multiple sclerosis disease-
modifying treatments for relative efficacy.
We have also demonstrated a negative time-dependent
effect of multiple sclerosis disease-modifying treatments,
which supports previous reports of increase in relapses
and case reports/series of clinical worsening (Papeix et al.,
2007; Shimizu et al., 2010; Uzawa et al., 2010; Barnett
et al., 2012; Kleiter et al., 2012; Min et al., 2012). We
have also demonstrated that 75% of EDSS 6.0 outcomes
and 79% of bilateral visual disability outcomes occur sub-
sequent to the onset attack demonstrating the potential for
reducing long-term disability. Thus, our study strengthens
the evidence for early IST in NMO. On the other hand,
given that 41% were blind in one eye after incident optic
neuritis and 17% remained wheelchair-bound or worse
after incident transverse myelitis, the development of regen-
erative and reparative strategies in the future warrants
emphasis.
Our study has several weaknesses and strengths. Firstly,
although all centres have prospectively collected databases,
the analysis was not preplanned and some data points were
occasionally missing. Some retrospectively collected relapses
were included particularly from the early phases of the dis-
ease before the diagnosis was made and this relied on pa-
tient reporting. The cases in this study may not be
representative of disease course and disability in the com-
munity (population-based). All centres except Matinique
(which is closest to population-based cohort with 31 preva-
lent cases from 2011) receive referrals from other centres so
the referral bias is likely to be similar among centres. It
would not be possible to perform a population-based
cohort study as the numbers of NMOSD patients in such
populations are too small to allow such a mathematical
analysis. There are only five patients in Olmsted County
with AQP4-IgG positive NMOSD. It is possible than
some may have been included in the Mayo cohort, but
given the small number, we doubt this would have any
significant effect.
Additionally, biases will exist due to patients lost to
follow-up although most centres will follow-up patients be-
cause they are on long-term immunosuppression. This bias
may lead to loss of some patients with milder disease and
may explain the variability in mortality rates depending on
the completeness of data obtained. However, these data
represent the outcomes within NMO specialist centres
across different countries that allow for different treatment
and follow-up practices making it more relevant to hetero-
geneous populations of NMO.
Our study supports onset age, onset phenotype and
ethnic influences on outcome in NMO and we offer a
prognostic tool for individual patients. In addition, we
have provided data for powering clinical treatment trials
based upon the relapse activity in the preceding 2 years
and suggest recruitment of ‘all comers’ would be a reason-
able approach. Finally, we have provided additional evi-
dence for the use of IST, especially at an early stage of
disease.
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